|
ZNF91 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.97619698383278E-14 |
| Normal-vs-Stage2 |
1.68850045056956E-10 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
1.67643676718399E-12 |
| Stage1-vs-Stage2 |
6.255200E-01 |
| Stage1-vs-Stage3 |
2.875800E-02 |
| Stage1-vs-Stage4 |
2.023800E-02 |
| Stage2-vs-Stage3 |
2.269600E-01 |
| Stage2-vs-Stage4 |
7.756100E-02 |
| Stage3-vs-Stage4 |
5.254200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.184200E-04 |
| Normal-vs-Asian |
7.3560046942589E-11 |
| Caucasian-vs-AfricanAmerican |
2.420400E-01 |
| Caucasian-vs-Asian |
6.626600E-01 |
| AfricanAmerican-vs-Asian |
3.833800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.10134124042816E-13 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
5.294400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(41-60Yrs) |
2.1316282072803E-14 |
| Normal-vs-Age(61-80Yrs) |
1.62925228863742E-12 |
| Normal-vs-Age(81-100Yrs) |
9.951000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.768600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.122000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.681800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.936000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.610800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.321000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.8130999996101E-07 |
| Classical-VS-Follicular |
2.184100E-02 |
| Classical-VS-Other |
3.722200E-01 |
| Classical-VS-Normal |
5.36981570320449E-12 |
| Tall-VS-Follicular |
1.38600000365585E-08 |
| Tall-VS-Other |
7.581500E-02 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
9.569600E-01 |
| Follicular-VS-Normal |
1.04119999999597E-06 |
| Other-VS-Normal |
1.951500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.44169137633799E-15 |
| Normal-vs-N1 |
2.52575738102223E-13 |
| N0-vs-N1 |
1.093800E-01 |
|
|
